Previous 10 | Next 10 |
ASLAN Pharmaceuticals (NASDAQ: ASLN ): Q1 GAAP EPS of -$0.02 beats by $0.10 . More news on: ASLAN Pharmaceuticals Limited, Earnings news and commentary, Healthcare stocks news, , Read more ...
SINGAPORE, May 11, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the first quarter ...
Gainers: Borqs Technologies (NASDAQ: BRQS ) +370% . More news on: Borqs Technologies, Inc., SCWorx Corp., NN, Inc., Stocks on the move, , Read more ...
ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment Study remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020 SINGAPORE, April 13, 202...
ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment Study remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020 SINGAPORE, April 13, 202...
Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...
ASLAN Pharmaceuticals (NASDAQ: ASLN ): Q4 GAAP EPS of -$0.07 beats by $0.12 . More news on: ASLAN Pharmaceuticals Limited, Earnings news and commentary, Healthcare stocks news, , Read more ...
SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the quarter and ...
SINGAPORE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company, today announced its presentation at the 9 th Annual SVB Leerink Global Healthcare Conference. Dr Carl Firth, Chie...
Gainers: WLL +7.3% . RRD +7.1% . RDFN +5.1% . ASLN +3.2% . TRIP +3.1% . More news on: Whiting Petroleum Corporation, R.R. Donnelley & Sons Company, Redfin Corporation, Stocks on the move, , , News on ETFs Read more ...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab . The findings will deepen understanding of the biology underlying the rece...
ASLAN management will present new data from the interim analysis of the TREK-DX study Register here to attend the webinar event on May 7, 2024 at...